[DOI] [PubMed] [Google Scholar] 29.Giusti I, Rughetti A, DAscenzo S, et al
In the head-to-head SURMOUNT-5 trial (NEJM 2025), tirzepatide produced 20.2% weight loss vs 13.7% for semaglutide
What is Sermorelin and why is it part of a longevity protocol
the 20% threshold was not part of the statistical testing hierarchy) Among the participants for whom data were available at the week 68 visit (1212 participants in the semaglutide group and 577 in the placebo group), these thresholds were reached by 86.4% (1047 participants), 69.1% (838 participants), 50.5% (612 participants), and 32.0% (388 participants), respectively, in the semaglutide group, as compared with 31.5% (182 participants), 12.0% (69 participants), 4.9% (28 participants) Participants who received semaglutide had a greater improvement with respect to cardiometabolic risk factors and a greater increase in participant-reported physical functioning from baseline than those who received placebo
Un paciente con enfermedades del tracto gastrointestinal, antecedentes de pancreatitis, o alergias a los componentes del frmaco no es candidato
